Synsorb Biotech Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Synsorb Biotech

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: David Zabrocki who wrote (12)	1/27/1997 11:24:00 AM
From: Fred J Bealle	of 32

David, Synsorb would be a very attractive takeover target. I would recommend buying it for just that reason; the recent surge in SYB could be related to such insider information as you mention. There has been no news on this from stockwatch. Alas, I have only 300 shares and the price has risen. Looks like there will be no corrections or dips. Review and approval: I've seen some brief summaries in Time or McLeans magazine. There must be some on the net. I will look. fred bealle --- analyst report: Synsorb Biotech Inc - In the News Van Sun's Lamphier says Yorkton analyst still keen Synsorb Biotech Inc SYB Shares issued 16084520 1997-01-24 close $11.5 Monday Jan 27 1997 In the News Market Monitor columnist Gary Lamphier says in a Reality Check in the Saturday edition of the Vancouver Sun that Yorkton Securities life sciences analyst Wayne Schnarr rated Synsorb Biotech as a buy at $8.15 on November 15. Mr Schnarr said that Synsorb has acquired an exclusive license on new technology which will allow the company to expand its portfolio to include sugar or carbohydrate-based compounds. He said that Synsorb can now expect a continuous stream of new products to enter the clinic and be developed using funds from the sale of its two lead products. He had a December 1997 target of $20. Synsorb shares rose $0.40 to $11.50 on Friday, down from a December high of $12.60. Mr Schnarr reiterated his buy recommendation in a report last Tuesday. He now has a 12 to 18-month target price of $25. Mr Schnarr says he believes that 1997 will be the year when the potential of Synsorb's two lead products is realized. He notes that Synsorb recently won approval from Canada's Health Protection Branch to conduct phase one and two clinical trials for its Synsorb Cd product. He also says he expects Synsorb to disclose phase three results and further licensing agreements for Synsorb Pk. toronto

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next